Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly.

Autor: Abad Pérez D; Internal Medicine Department, University Hospital de Getafe, Carretera de Madrid-Toledo, Madrid, Spain. danielabadperez@hotmail.com., García Polo I; Internal Medicine Department, University Hospital La Princesa, Madrid, Spain., Rodríguez Salvanés FJ; Admision and Documentary Department, University Hospital La Princesa, Madrid, Spain., Bellisco Roncal S; Internal Medicine Department, University Hospital La Princesa, Madrid, Spain., Ibáñez Sanz P; Internal Medicine Department, University Hospital La Princesa, Madrid, Spain., Suárez Fernández C; Internal Medicine Department, University Hospital La Princesa, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of human hypertension [J Hum Hypertens] 2022 Feb; Vol. 36 (2), pp. 163-170. Date of Electronic Publication: 2021 Apr 13.
DOI: 10.1038/s41371-021-00498-4
Abstrakt: Hypertension is one of the main cardiovascular risk factors. In the elderly, the most common form is isolated systolic hypertension, a consequence of the increase in arterial stiffness. None of the antihypertensives currently used affects arterial stiffness, whereas nitrates seem to have an effect. The aim of this work was to assess their effect on elderly patients with uncontrolled isolated systolic hypertension, defined as systolic blood pressure over 140 mmHg and diastolic blood pressure under 90 mmHg. The present study is a phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial, conducted at the University Hospital La Princesa in Madrid. Patients of both sexes, aged 65 years or older, with poorly controlled isolated systolic hypertension, were treated with 40-60 mg of sustained-release isosorbide mononitrate or matching placebo for 12 weeks. The main objective was to assess the effect on clinical pulse pressure (PP); in addition, its effect on vascular function was evaluated. Analysis was performed by intention to treat. The study was registered at the European Union Clinical Trials Register (EUDRACT 2012-002988-10) and was funded by the Spanish Ministry of Health. A total of 58 patients with an average age of 77 years were enrolled, 32 were treated with nitrate, and 26 with placebo. No significant differences were found either in PP decline (5.28 vs 7.49 mmHg, p = 0.79) or in other variables, including parameters of vascular function. There were no differences in adverse events. The results of this study have not confirmed the benefit of nitrate treatment in isolated systolic hypertension or the improvement of vascular function.
(© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: